<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2019-08-06">2019 August 06.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Robert</forename><forename type="middle">J</forename><surname>Motzer</surname></persName>
							<email>motzerr@mskcc.org</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Memorial Sloan Kettering Cancer Center</orgName>
								<address>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department">Corresponding author. Department of Oncology</orgName>
								<orgName type="institution">Memorial Sloan Kettering Cancer Center</orgName>
								<address>
									<addrLine>1275 York Ave</addrLine>
									<postCode>10065</postCode>
									<settlement>New York</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alain</forename><surname>Ravaud</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">Bordeaux University Hospital</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jean-Jacques</forename><surname>Patard</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Centre Hospitalier De Mont De Marsan</orgName>
								<address>
									<settlement>Mont-de-Marsan</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hardev</forename><forename type="middle">S</forename><surname>Pandha</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Clinical and Experimental Medicine and Department of Microbial Sciences</orgName>
								<orgName type="institution">University of Surrey</orgName>
								<address>
									<settlement>Guildford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniel</forename><forename type="middle">J</forename><surname>George</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Division of Oncology</orgName>
								<orgName type="department" key="dep2">Duke Cancer Center</orgName>
								<address>
									<settlement>Durham</settlement>
									<region>NC</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anup</forename><surname>Patel</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">Spire Roding Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yen-Hwa</forename><surname>Chang</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Taipei Veterans General Hospital</orgName>
								<address>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bernard</forename><surname>Escudier</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Medical Oncology</orgName>
								<orgName type="institution">Institut Gustave Roussy</orgName>
								<address>
									<settlement>Villejuif</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frede</forename><surname>Donskov</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Aarhus University Hospital</orgName>
								<address>
									<settlement>Aarhus</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ahmed</forename><surname>Magheli</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Charité Universitaetsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Giacomo</forename><surname>Carteni</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Division of Oncology and Division of Urology</orgName>
								<orgName type="institution">Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli</orgName>
								<address>
									<settlement>Naples</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brigitte</forename><surname>Laguerre</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Medical Oncology</orgName>
								<orgName type="institution">Centre Eugene Marquis</orgName>
								<address>
									<settlement>Rennes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Piotr</forename><surname>Tomczak</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Klinika Onkologii Oddzial Chemioterapii</orgName>
								<address>
									<settlement>Poznan</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Breza</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Slovak Medical University</orgName>
								<address>
									<settlement>Bratislava, Bratislava</settlement>
									<country key="SK">Slovakia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paola</forename><surname>Gerletti</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Mariajose</forename><surname>Lechuga</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Xun</forename><surname>Lin</surname></persName>
							<affiliation key="aff15">
								<orgName type="institution">Pfizer Inc</orgName>
								<address>
									<settlement>La Jolla</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michelle</forename><surname>Casey</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution">Pfizer Inc</orgName>
								<address>
									<settlement>Collegeville</settlement>
									<region>PA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lucile</forename><surname>Serfass</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Pfizer Oncology</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Allan</forename><forename type="middle">J</forename><surname>Pantuck</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">Ronald Reagan UCLA Medical Center</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Staehler</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution">University Hospital of Munich</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">O</forename><surname>Pfizer</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Pfizer Oncology</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><forename type="middle">R L</forename><surname>Milan</surname></persName>
						</author>
						<author>
							<persName><surname>Motzer</surname></persName>
						</author>
						<author>
							<persName><surname>Ravaud</surname></persName>
						</author>
						<author>
							<persName><surname>Patard</surname></persName>
						</author>
						<author>
							<persName><surname>Pandha</surname></persName>
						</author>
						<author>
							<persName><surname>George</surname></persName>
						</author>
						<author>
							<persName><surname>Patel</surname></persName>
						</author>
						<author>
							<persName><roleName>Escudier, Donskov, Magheli, Carteni, Laguerre, Tomczak, Breza, Pantuck, Staehler.</roleName><surname>Chang</surname></persName>
						</author>
						<author>
							<affiliation key="aff14">
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2019-08-06">2019 August 06.</date>
						</imprint>
					</monogr>
					<idno type="MD5">82614A67BB2E1BF963992988BDAA5399</idno>
					<idno type="DOI">10.1016/j.eururo.2017.09.008</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:09+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Lin, Casey. Obtaining funding: Serfass. Administrative, technical, or material support: Serfass, Lechuga, Gerletti. Supervision: Serfass, Lechuga, Gerletti. Other: None Adjuvant</term>
					<term>Disease-free survival</term>
					<term>Renal cell carcinoma</term>
					<term>Sunitinib</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Robert J. Motzer had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</s><s>Study concept and design: Motzer, Ravaud, Lechuga, Serfass.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p><s>The prognosis for renal cell carcinoma (RCC) depends on stage and on additional tumor and patient-specific risk factors obtained at diagnosis.</s><s>Nearly 20% of all patients with RCC are diagnosed with locoregional disease <ref type="bibr" target="#b0">[1]</ref>, and up to 40% of these patients experience relapse after nephrectomy and develop metastasis <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>Adjuvant therapies to decrease relapse after nephrectomy are needed.</s><s>A decision to adopt a new adjuvant therapy in standard clinical practice depends on consideration of a patient's estimated risk of recurrence, the clinical benefit of the additional treatment, and the additive treatment related morbidity.</s></p><p><s>In the phase 3 S-TRAC study, sunitinib (50 mg once daily) was administered on a 4-wk on/2-wk off treatment schedule to patients with locoregional RCC at high risk of tumor recurrence after nephrectomy <ref type="bibr" target="#b3">[4]</ref>.</s><s>Adjuvant sunitinib significantly improved disease-free survival (DFS) versus placebo (median 6.8 vs 5.6 yr) according to blinded independent central review (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.59-0.98;</s><s>p = 0.03) <ref type="bibr" target="#b3">[4]</ref>.</s><s>At 5 yr, the DFS rate gain was 8% in favor of sunitinib over placebo.</s><s>Overall survival (OS) data were not mature at data cutoff <ref type="bibr" target="#b3">[4]</ref>.</s><s>The most common (&gt;5% of patients) grade ≥3, all-causality adverse events (AEs) in the sunitinib group were palmar-plantar erythrodysesthesia (16%), neutropenia (8.5%), hypertension (7.8%), and thrombocytopenia (6.2%) <ref type="bibr" target="#b3">[4]</ref>.</s></p><p><s>In the present study, we examined treatment outcomes for subgroups of patients defined according to baseline characteristics, and report here the sites of tumor recurrence in the two treatment arms.</s><s>Updated OS data, based on an additional 10 mo of follow-up, are also provided.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Patients and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Patients and treatment</head><p><s>As described previously <ref type="bibr" target="#b3">[4]</ref>, key inclusion criteria in the S-TRAC study included: nonmetastatic locoregional RCC defined as T3 or T4, no or undetermined nodal involvement, or any T stage with local nodal involvement; and for all patients, any Fuhrman grade and any Eastern Cooperative Oncology Group performance status (ECOG PS).</s><s>In addition, patients had to have clear cell histology, no previous systemic therapy, ECOG PS ≤2 before nephrectomy, no evidence of macroscopic residual disease/metastasis (confirmed by blinded independent central review), and treatment initiation within 3-12 wk after nephrectomy.</s><s>Patients were randomized to receive treatment with sunitinib or placebo for nine cycles (~1 yr) until recurrence, second cancer, significant toxicity, or consent withdrawal.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Analyses</head><p><s>Disease recurrence was determined via centrally confirmed imaging and/or histological findings.</s><s>Prespecified subgroup analyses of DFS by baseline risk factors were conducted using a Cox proportional hazards model.</s><s>The baseline risk factors were as follows: University of California Los Angeles integrated staging system (UISS) criteria <ref type="bibr" target="#b4">[5]</ref>; age; gender; ECOG PS before first dose (as opposed to ECOG PS in risk groups before nephrectomy); weight; and neutrophil-to-lymphocyte ratio).</s><s>Post hoc analyses of DFS by Fuhrman grade were also performed.</s><s>Interaction terms (treatment × baseline factors) were analyzed to investigate possible interactions between treatment and the baseline factors in a univariate model.</s><s>All subgroup analyses were exploratory, and no adjustments for multiplicity were made.</s></p><p><s>Patients were followed for survival status (regardless of treatment duration) every 12 wk until the time of the final analysis.</s><s>OS was defined as the time from the date of randomization to the date of death due to any cause.</s><s>In the absence of confirmation of death, survival time was censored at the last date on which the patient was known to be alive.</s><s>OS was estimated using the Kaplan-Meier method, and data were compared using a two-sided log-rank test, stratified by UISS risk group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Patients and treatment</head><p><s>Overall, 615 patients (n = 309 sunitinib; n = 306 placebo) were enrolled from 97 sites, including 73 in Europe, 15 in Asia, and nine in the Americas.</s><s>Of these patients, 306 were treated with sunitinib and 304 with placebo.</s><s>Patient characteristics, summary of treatment, and treatment outcome are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Overall, 71% of patients received sunitinib for six or more cycles (8 mo) and 56% completed the full 1-yr treatment.</s><s>It should be noted that the trial permitted a dose decrease to 37.5 mg/d, but not to 25 mg/d.</s><s>The most common reasons for treatment discontinuation in the sunitinib group included AEs (28%), relapse (7.2%), and patient refusal to continue treatment for reason other than AEs (4.6%).</s><s>In the placebo-treated patients, the most common reasons for treatment discontinuation included relapse (19%), AEs (5.9%), and patient refusal to continue treatment for a reason other than AEs (2.6%).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Subgroup analysis</head><p><s>The majority of subgroups selected according to baseline characteristics experienced longer DFS on sunitinib compared to placebo (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>Subgroups favoring sunitinib by HR with an upper 95% CI boundary &lt;1.0 included age &lt;45 yr (HR 0.43, 95% CI, 0.20-0.92)</s><s>or ≥65 yr (HR 0.59, 95% CI 0.36-0.95);</s><s>normal weight (HR 0.63, 95% CI 0.41-0.96);</s><s>and ECOG PS 0 (HR 0.69, 95% CI 0.51-0.93).</s><s>Other groups included Fuhrman grade 3 or 4 tumors (HR 0.73, 95% CI 0.55-0.98);</s><s>higher risk (HR 0.74, 95% CI 0.55-0.99;</s><s>Fig. <ref type="figure" target="#fig_1">2</ref>); and neutrophilto-lymphocyte ratio ≤3 (HR 0.72, 95% CI 0.54-0.95).</s><s>The CIs were wide for the subgroups because of the small sample size.</s><s>In addition, none of the interaction terms (treatment × baseline factors) were statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Site of relapse</head><p><s>According to blinded independent review, 97 patients in the sunitinib arm and 122 patients in the placebo arm developed distant disease recurrence.</s><s>The most common (≥5%) sites of distant recurrence were lung and lymph node (Table <ref type="table" target="#tab_1">2</ref>).</s><s>There was no difference in sites of recurrence between the treatment arms.</s><s>In 219 recurrences observed across both arms, 89, 47, 36, and 25 occurred in lung, lymph node, retroperitoneum, and liver, respectively.</s><s>Only ten and seven recurrences were observed in bone and brain, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">Overall survival</head><p><s>At the cutoff date for the updated OS analysis (January 31, 2017), 67 patients in the sunitinib arm and 74 patients in the placebo arm had died.</s><s>The median follow-up time was 6.6 yr in the sunitinib arm and 6.7 yr in the placebo arm.</s><s>The median OS was not reached in either arm.</s><s>The HR for sunitinib versus placebo was 0.92 (95% CI 0.66-1.28;</s><s>p = 0.6; Fig. <ref type="figure" target="#fig_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p><s>Results from this report on the S-TRAC study show that 71% of patients completed 8 mo of adjuvant sunitinib treatment and 56% completed the full year of treatment.</s><s>Of the treatment discontinuations reported for the sunitinib arm, 28% were related to AEs, which is similar to the discontinuation rate reported for sunitinib in the metastatic RCC setting <ref type="bibr" target="#b5">[6]</ref>.</s><s>Furthermore, the 28% discontinuation rate reported in S-TRAC was over a median treatment duration of 12 mo, whereas in the metastatic setting, discontinuation rates of 24% and 20% due to AEs were reported for pazopanib and sunitinib, respectively, over a median treatment duration of 8 mo <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b5">6]</ref>.</s><s>For most patients, toxicities related to adjuvant sunitinib were managed via supportive care and a dose reduction or interruption.</s><s>Nevertheless, there is still a need to improve the management of some side effects in the adjuvant setting.</s><s>For example, hand-foot syndrome occurred more frequently in the adjuvant than in the metastatic setting <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref>.</s><s>Whether this is because of a more physically active population receiving treatment in the adjuvant setting or a more specific toxicity is not yet clear.</s><s>In addition, an alternative schedule (2 wk on treatment followed by 1 wk off treatment) should be explored with the aim of decreasing the frequency of side effects and severity, as reported in the metastatic setting <ref type="bibr" target="#b8">[9]</ref>.</s></p><p><s>In addition to the positive outcome in the overall population of the S-TRAC study, the majority of subgroups defined according to baseline characteristics experienced longer DFS on sunitinib compared to placebo, including the prespecified subgroup of patients with higher risk of recurrence (defined as T3, no or undetermined nodal involvement, Fuhrman grade ≥2, and ECOG PS ≥1; or T4 and/or nodal involvement) compared to the overall population, as well as the subgroup of patients with Fuhrman grade 3/4.</s><s>This analysis has limitations in that all the subgroup analyses were exploratory, and no adjustments for multiplicity were made.</s><s>However, the results are consistent with the primary analysis, showing a benefit for adjuvant sunitinib treatment in patients at high risk of recurrent RCC after nephrectomy.</s></p><p><s>Overall, 31% and 40% of patients in the sunitinib and placebo arms, respectively, developed distant disease recurrence.</s><s>The most common sites of relapse included lung, lymph node, and retroperitoneum.</s><s>Bone and brain metastases (1% each) were less common after adjuvant sunitinib compared to the higher percentages documented in metastatic RCC (30% for bone and 8% for brain) <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b10">11]</ref>.</s><s>Knowing the patterns of recurrence in these patients may help physicians to monitor patients who are deemed at high risk of recurrence for metastases following nephrectomy.</s></p><p><s>The updated OS data were not mature after an additional 10 mo of follow-up, but the results show that OS was not compromised.</s><s>With a 40% survival rate at 10 yr after nephrectomy in patients at high risk (UISS criteria) of recurrent RCC <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b12">13]</ref>, and given the number of patients and timeframe required, this study was not powered to show an improvement in OS.</s></p><p><s>Specifically, a trial designed to demonstrate a 25% improvement in OS (HR 0.8) with a twosided α value of 0.05 and 80% power would require approximately 1650 patients and 18.5 yr of follow-up.</s><s>This is a conservative estimate that does not account for the dropouts that are likely in a study that is ongoing over this time period.</s><s>Although improving patient OS is a goal of adjuvant treatment, it is widely understood that for many indications for which survival is long and/or many subsequent therapies are available, it is challenging to measure.</s><s>Therefore, adjuvant treatments in various tumor types, including colon cancer, breast cancer, melanoma, and gastrointestinal stromal tumors, have been approved by regulatory authorities and implemented as a standard of care on the basis of relative risk reductions in DFS or recurrence-free survival with limited or no OS data <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref>.</s><s>Approval was based on, among other reasons, the strength/magnitude of the benefit, positive risk-benefit assessment, and unmet medical needs.</s><s>Indeed, for colon cancer and gastrointestinal stromal tumors, the benefit in DFS later translated to a benefit in OS <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20]</ref>.</s></p><p><s>The phase 3 studies ASSURE and S-TRAC assessed the efficacy of adjuvant sunitinib versus placebo in patients with RCC, but had different outcomes for the primary endpoint analysis <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b20">21]</ref>.</s><s>In ASSURE, there was no improvement in investigator-assessed DFS <ref type="bibr" target="#b20">[21]</ref>, whereas independently assessed DFS improved significantly in S-TRAC <ref type="bibr" target="#b3">[4]</ref>.</s><s>Differences between the ASSURE and S-TRAC studies are summarized in Table <ref type="table">3</ref>.</s><s>In addition to the differences described therein, the difference in DFS according to investigator assessment for the placebo arms (median 6.6 yr in ASSURE and 4.5 yr in S-TRAC) illustrates the differences in the patient populations <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b20">21]</ref>.</s></p><p><s>One subgroup analysis for ASSURE did not elucidate a group that benefited from treatment with sunitinib <ref type="bibr" target="#b21">[22]</ref>.</s><s>However, the differences between ASSURE and S-TRAC in trial design, patient population, and dosing should be considered in conglomerate rather than in isolation <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b20">21]</ref>.</s><s>For example, owing to the differences in dosing observed across the two trials, subgroup analyses based on exposure in ASSURE may not explain the benefit observed in S-TRAC <ref type="bibr" target="#b21">[22]</ref>.</s><s>Cross-study comparison between subsets of patients selected retrospectively from the ASSURE trial and the primary analysis of S-TRAC must be interpreted with caution given the many differences between the two trials and the limitations of such comparisons.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Conclusions</head><p><s>The DFS benefit with adjuvant sunitinib for in patients with locoregional RCC at high risk of tumor recurrence after nephrectomy as demonstrated in the primary analysis for S-TRAC was supported by subgroup analyses.</s><s>The majority of subgroups experienced longer DFS with adjuvant sunitinib compared to placebo, including patients at higher risk of recurrence (T3, no or undetermined nodal involvement, Fuhrman grade ≥2, and ECOG PS ≥1; or T4 and/or nodal involvement) and those with Fuhrman grade 3/4.</s><s>The updated OS data are not mature enough to draw reliable conclusions regarding the impact of adjuvant sunitinib treatment on OS; however, no detrimental effect on OS was observed for sunitinib treatment.</s><s>Disease-free survival by subgroup.</s><s>* T3 tumor, no or undetermined nodal involvement, no metastasis, any Fuhrman grade, ECOG PS 0; or Fuhrman grade 1, ECOG PS 1. † T3 tumor, no or undetermined nodal involvement, no metastasis, Fuhrman grade ≥2, ECOG PS ≥1.</s><s>‡ T4 tumor or any T stage with nodal involvement, no metastasis, any Fuhrman grade, any ECOG PS.</s><s>BMI = body mass index; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; HR = hazard ratio; NLR = neutrophil-tolymphocyte ratio; UISS = University of California Los Angeles integrated staging system.</s><s>Disease-Free survival in patients at higher risk according to blinded independent central review.</s><s>Higher risk was defined as T3, no or undetermined nodal involvement, no metastasis, Fuhrman grade ≥2, ECOG PS ≥1; or T4 and/or nodal involvement.</s><s>CI = confidence interval; HR = hazard ratio; DFS = disease-free survival; NR = not reached.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 -.</s></p></div></figDesc><graphic coords="9,85.83,62.00,500.33,347.76" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc><div><p><s>Fig. 2 -.</s></p></div></figDesc><graphic coords="10,87.99,62.00,496.03,345.60" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 -</head><label>3</label><figDesc><div><p><s>Fig. 3 -.Kaplan-Meier estimates of overall survival (OS) in the intent-to-treat population.</s><s>* Twosided p value from log-rank test stratified by University of California, Los Angeles integrated staging system high-risk group: T3 or T4, no or undetermined nodal involvement, no metastasis, or any T stage with local nodal involvement, and for all patients, any Fuhrman grade and any Eastern Cooperative Oncology Group performance status.</s><s>CI = confidence interval; ECOG PS =; HR = hazard ratio; NR = not reached.</s></p></div></figDesc><graphic coords="11,84.00,62.00,504.00,318.72" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 -</head><label>1</label><figDesc><div><p><s>S-TRAC selected baseline characteristics and summary of study outcome CI = confidence interval; DFS = disease-free survival; ECOG PS = Eastern Cooperative Oncology Group performance status; NR = not reached; UCLA = University of California Los Angeles.</s><s>a T3, no or undetermined nodal involvement, no metastasis, any Fuhrman grade, ECOG PS 0 or Fuhrman grade 1, ECOG PS 1. b T3, no or undetermined nodal involvement, no metastasis, Fuhrman grade ≥2, ECOG PS ≥1.</s><s>c T4 or any T with nodal involvement, no metastasis, any Fuhrman grade, any ECOG PS.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Sunitinib</cell><cell>Placebo</cell></row><row><cell cols="5">Patients assigned for treatment/treated (n)</cell><cell>309/306</cell><cell>306/304</cell></row><row><cell cols="5">Median age, yr (interquartile range)</cell><cell>57 (49-64)</cell><cell>58 (51-66)</cell></row><row><cell cols="3">Male/female (%)</cell><cell></cell><cell>72/28</cell><cell>75/25</cell></row><row><cell cols="3">ECOG PS, n (%)</cell><cell></cell></row><row><cell>0</cell><cell></cell><cell></cell><cell></cell><cell>228 (74)</cell><cell>220 (72)</cell></row><row><cell>1</cell><cell></cell><cell></cell><cell></cell><cell>79 (26)</cell><cell>84 (28)</cell></row><row><cell>≥2</cell><cell></cell><cell></cell><cell></cell><cell>1 (0.3)</cell><cell>0</cell></row><row><cell cols="5">UCLA integrated staging system, n (%)</cell></row><row><cell>T3 low</cell><cell cols="2">a</cell><cell></cell><cell>115 (37)</cell><cell>112 (37)</cell></row><row><cell cols="2">T3 high</cell><cell>b</cell><cell></cell><cell>165 (53)</cell><cell>166 (54)</cell></row><row><cell cols="3">T4 or any T/N+</cell><cell>c</cell><cell>29 (9.4)</cell><cell>28 (9.2)</cell></row><row><cell cols="5">Patients who completed full 1-yr treatment, n (%)</cell><cell>170 (56)</cell><cell>211 (69)</cell></row><row><cell cols="5">Median treatment duration, mo (interquartile range)</cell><cell>12.4 (6.0-12.5)</cell><cell>12.4 (9.2-12.5)</cell></row><row><cell cols="5">Median daily dose, mg (interquartile range)</cell><cell>45.9 (38.4-50)</cell><cell>50 (49-50.2)</cell></row><row><cell cols="4">Median DFS, yr (95% CI)</cell><cell>d</cell><cell>6.8 (5.8-NR)</cell><cell>5.6 (3.8-6.6)</cell></row><row><cell cols="5">DFS hazard ratio (95% CI) for sunitinib vs placebo</cell><cell>d 0.76 (0.59-0.98)</cell></row></table><note><p><s>d According to blinded independent central review.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 -</head><label>2</label><figDesc><div><p><s>Most common (≥1% of patients in any group) sites of distant recurrence</s></p></div></figDesc><table><row><cell>Site of relapse</cell><cell>Patients, n (%)</cell><cell></cell></row><row><cell></cell><cell cols="2">Sunitinib (n = 309) Placebo (n = 306)</cell></row><row><cell>Lung</cell><cell>40 (13)</cell><cell>49 (16)</cell></row><row><cell>Lymph node</cell><cell>21 (6.8)</cell><cell>26 (8.5)</cell></row><row><cell>Retroperitoneum</cell><cell>16 (5.2)</cell><cell>20 (6.5)</cell></row><row><cell>Liver</cell><cell>11 (3.6)</cell><cell>14 (4.6)</cell></row><row><cell>Adrenal gland</cell><cell>10 (3.2)</cell><cell>6 (2)</cell></row><row><cell>Bone</cell><cell>3 (1)</cell><cell>7 (2.3)</cell></row><row><cell>Pancreas</cell><cell>4 (1.3)</cell><cell>5 (1.6)</cell></row><row><cell>Brain</cell><cell>3 (1)</cell><cell>4 (1.3)</cell></row><row><cell cols="2">Peritoneum/omentum 3 (1)</cell><cell>4 (1.3)</cell></row><row><cell>Mediastinum</cell><cell>1 (0.3)</cell><cell>4 (1.3)</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Eur Urol. Author manuscript; available in PMC 2019 August 06.</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">c T3 or T4, no or undetermined nodal involvement, no metastasis, or any T stage with local nodal involvement; and for all patients, any Fuhrman grade and any ECOG PS. d The remaining patients started at a reduced dose of 37.5 mg.Eur Urol. Author manuscript; available in PMC 2019 August 06.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>Patients treated at the Memorial Sloan Kettering Cancer Center were supported in part by a Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748).</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Funding/Support and role of the sponsor: These analyses were designed, funded, and conducted by Pfizer.</s><s>The S-TRAC study from which data were collected for these analyses was sponsored by Pfizer.</s><s>Medical writing support was provided by Vardit Dror of Engage Scientific Solutions and was funded by Pfizer Inc.</s><s>The sponsor played a role in the design and conduct of the study; data collection, management, and analysis; and review and approval of the manuscript.</s></p><p><s>Financial disclosures: Robert J. Motzer certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Robert J. Motzer has received research funding and consultant fees from Pfizer.</s><s>Alain Ravaud is a member of advisory boards on renal cell carcinoma for Pfizer, Novartis, GSK, Roche, and BMS; has received institutional support grants from Pfizer and Novartis, and meetings expenses from Pfizer, Novartis, BMS, AstraZeneca, and MSD.</s><s>Jean-Jacques Patard has received consulting fees from Pfizer and GSK.</s><s>Daniel J. George has received honoraria and consulting fees from Dendreon, Sanofi, Novartis, and Bayer; consulting fees from Medivation, Merck, and Genentech; grants from Genentech/Roche, Novartis, Janssen, Astellas, Celldex, and Acerta; and grants and consulting fees from Exelixis, Pfizer, Sanofi, Innocrin Pharma, and BMS.</s><s>Bernard Escudier has received consulting fees from Bayer, Pfizer, and Novartis; and honoraria from Bayer, Roche, Pfizer, Genentech, Novartis, and AVEO.</s><s>Frede Donskov has received research funding from Pfizer, Novartis, and GSK.</s><s>Ahmed Magheli has received financial compensation for speeches from Janssen, Bayer, Astellas, and Pfizer.</s><s>Brigitte Laguerre has received honoraria from Pfizer.</s><s>Michelle Casey, Paola Gerletti, Mariajose Lechuga, Xun Lin, and Lucile Serfass are employees of and own stock in Pfizer.</s><s>Allan J. Pantuck has received consulting fees from Pfizer.</s><s>Michael Staehler has received honoraria, consulting fees, and research grants from Pfizer, Bayer, GSK, Roche, BMS, Novartis, Exelixis, and AVEO.</s><s>Hardev S. Pandha has received honoraria for advisory work from Ipsen and Esai.</s><s>Piotr Tomczak, Giacomo Carteni, Jan Breza, Anup Patel, and Yen-Hwa Chang have nothing to disclose.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose administered</head><p><s>Starting dose levels 2 (50 mg and 37. b pT1b, G3-4, no or undetermined nodal involvement, no metastasis, or any T, any G, with local nodal involvement (fully resected), and no metastasis.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">SEER cancer statistics factsheets: kidney and renal pelvis cancer</title>
		<ptr target="http://seer.cancer.gov/statfacts/html/kidrp.html" />
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
		<respStmt>
			<orgName>National Cancer Institute</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Adjuvant therapy in renal cell carcinoma-past, present, and future</title>
		<author>
			<persName><forename type="first">T</forename><surname>Janowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Welsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mulders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Eisen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Oncol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="482" to="491" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23972712</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Janzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Figlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Belldegrun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Urol Clin North Am</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="843" to="852" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note>PubMed: 14680319</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ravaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Motzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Pandha</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="2246" to="2254" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27718781</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Improved prognostication of renal cell carcinoma using an integrated staging system</title>
		<author>
			<persName><forename type="first">A</forename><surname>Zisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Pantuck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dorey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1649" to="1657" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note>PubMed: 11250993</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Pazopanib versus sunitinib in metastatic renal-cell carcinoma</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Motzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hutson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="722" to="731" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23964934</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Gore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Szczylik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Porta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="757" to="763" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19615940</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Motzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Hutson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tomczak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">356</biblScope>
			<biblScope unit="page" from="115" to="124" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17215529</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bracarda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Negrier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Casper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Anticancer Ther</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="227" to="233" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>PubMed: 28044472</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Gore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Szczylik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Porta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="12" to="19" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 26086878</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Distribution of metastatic sites in renal cell carcinoma: a population-based analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bianchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jeldres</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="973" to="980" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 21890909</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Galligioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Quaia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Merlo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="2560" to="2566" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note>PubMed: 8640706</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases</title>
		<author>
			<persName><forename type="first">C</forename><surname>Giberti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Oneto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Martorana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rovida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Carmignani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Urol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="40" to="48" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note>PubMed: 9032533</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer</title>
		<author>
			<persName><forename type="first">T</forename><surname>Andre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Boni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mounedji-Boudiaf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page" from="2343" to="2351" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15175436</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial</title>
		<author>
			<persName><forename type="first">T</forename><surname>Andre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Boni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Navarro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="3109" to="3116" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19451431</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Dematteo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Ballman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Antonescu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="1097" to="1104" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19303137</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Prolonged survival in stage iii melanoma with ipilimumab adjuvant therapy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Eggermont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Chiarion-Sileni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Grob</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="1845" to="1855" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27717298</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Eggermont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Chiarion-Sileni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Grob</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="522" to="530" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25840693</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial</title>
		<author>
			<persName><forename type="first">H</forename><surname>Joensuu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sundby</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">307</biblScope>
			<biblScope unit="page" from="1265" to="1272" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22453568</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial</title>
		<author>
			<persName><forename type="first">H</forename><surname>Joensuu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Eriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sundby</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="244" to="250" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 26527782</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Haas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Manola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Uzzo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="2008" to="2016" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 26969090</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial JAMA Oncol</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Haas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Manola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Dutcher</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamaoncol.2017.0076</idno>
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
